Metagenomi Therapeutics (MGX) Other Non-Current Liabilities (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Other Non-Current Liabilities of $2.0 million for Q1 2026, down 7.4% year-over-year from $2.1 million in Q1 2025, and little changed quarter-over-quarter from $2.0 million in Q4 2025.
Metagenomi Therapeutics (MGX) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Other Non-Current Liabilities for 4 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 7.4% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (down 7.4% YoY), while the FY2025 annual figure was $2.0 million, down 2.84% from the prior year.
- Other Non-Current Liabilities steadied at $2.0 million in Q1 2026 per MGX's latest filing, from $2.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $5.1 million in Q4 2023 and bottomed at $1.9 million in Q3 2025.
- Historically, Other Non-Current Liabilities has averaged $2.9 million across 4 years, with a median of $2.1 million in 2025.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities slumped 60.43% — and 2025, when it dropped 2.84%.
- Metagenomi Therapeutics' Other Non-Current Liabilities stood at $5.1 million in 2023, then plunged by 60.43% to $2.0 million in 2024, then fell by 2.84% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
- Business Quant data shows MGX's Other Non-Current Liabilities at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.02 Mn |
| Mar 31, 2026 | 1.95 Mn |
| Dec 31, 2025 | 1.95 Mn |
| Sep 30, 2025 | 1.92 Mn |
| Jun 30, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 2.01 Mn |
| Sep 30, 2024 | 3.08 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Mar 31, 2024 | 5.08 Mn |
| Dec 31, 2023 | 5.08 Mn |